Antibody Information
General Information of This Antibody
| Antibody ID | ANI0LXGFW |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | MEDI-4276 |
|||||
| Synonyms |
MEDI-4276 antibody; Trastuzumab scFv+fully human IgG1 39S heavy chain biparatopic tetravalent mAb
Click to Show/Hide
|
|||||
| Antibody Type | Biparatopic tetravalent antibody (BtAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa |
|||||
| Antigen Name | Receptor tyrosine-protein kinase erbB-2 (HER2 ECD2); Receptor tyrosine-protein kinase erbB-2 (HER2 ECD4) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
MEDI4276 [Phase 1/2 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligibility requires HER2+ advanced breast/gastric cancer patients (age≥18) with prior HER2-targeted therapy and measurable disease (RECIST 1.1), excluding recent anticancer treatment (<28 days), excessive anthracycline exposure, or active brain metastases.
|
||||
| Administration Dosage |
Participants received IV dose of 0.05 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02576548 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1/2 Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogencity, and Antitumor Activity of MEDI4276 in Subjects With Select HER2-expressing Advanced Solid Tumors
|
||||
| Primary Endpoint |
Primary endpoints include safety assessment (AEs/SAEs/DLTs) to determine MTD, with monitoring through 90 days post-MEDI4276 dose, covering lab tests, vital signs, and ECGs for comprehensive safety profile evaluation.
|
||||
| Other Endpoint |
Secondary objectives evaluate efficacy (ORR/PFS/OS over 3 years) and PK/immunogenicity (Cmax/AUC/ADA incidence within 30 days post-treatment), measuring tumor response and drug exposure while tracking antibody development.
|
||||
References